EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors
Science Advances · 2023-12 · 9 (48)
DOI: 10.1126/sciadv.adg9721 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2023-12. Verfasst von Dan Li und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms, Glandular and Epithelial. Die Arbeit wurde bisher 102-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The efficacy of CAR-T cells for solid tumors is unsatisfactory. EpCAM is a biomarker of epithelial tumors, but the clinical feasibility of CAR-T therapy targeting EpCAM is lacking. Here, we report pre- and clinical investigations of EpCAM–CAR-T cells for solid tumors. We demonstrated that EpCAM–CAR-T cells costimulated by Dectin-1 exhibited robust antitumor activity without adverse effects in xenograft mouse models and EpCAM-humanized mice. Notably, in clinical trials for epithelial tumors (NCT02915445), 6 (50%) of the 12 enrolled patients experienced self-remitted grade 1/2 toxicities, 1 patient (8.3%) experienced reversible grade 3 leukopenia, and no higher-grade toxicity reported. Efficacy analysis determined two patients as partial response. Three patients showed >23 months of progression-free survival, among whom one patient experienced 2-year progress-free survival with detectable CAR-T cells 200 days after infusion. These data demonstrate the feasibility and tolerability of EpCAM–CAR-T therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
- Department of Oncology, Shanghai Tenth Peoples' Hospital, Shanghai, China.
- Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China.
- Department of Head and Neck Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
- Department of Radiation Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
ORCID-Profile: Dan Li, Xianling Guo, Kun Yang, Yuening Yang, Weilin Zhou, Yong Huang, Huashan Shi, Aiping Tong, Nianyong Chen, Jiankun Hu, Qing Xu, Yu-Quan Wei, Wei Wang
Zitieren
APA
Li, D., Guo, X., Yang, K., Yang, Y., Zhou, W., Huang, Y., Liang, X., Su, J., Jiang, L., Li, J., Fu, M., He, H., Yang, J., Shi, H., Yang, H., Tong, A., Chen, N., Hu, J., Xu, Q., …, & Wang, W. (2023). EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors. Science Advances, 9(48). https://doi.org/10.1126/sciadv.adg9721
Vancouver
Li D, Guo X, Yang K, Yang Y, Zhou W, Huang Y, et al. EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors. Science Advances. 2023;9(48). doi:10.1126/sciadv.adg9721
BibTeX
@article{Li2023,
author = {Li, Dan and Guo, Xianling and Yang, Kun and Yang, Yuening and Zhou, Weilin and Huang, Yong and Liang, Xiao and Su, Jinhua and Jiang, Lin and Li, Jing and Fu, Maorong and He, Haixia and Yang, Jinrong and Shi, Huashan and Yang, Hanshuo and Tong, Aiping and Chen, Nianyong and Hu, Jiankun and Xu, Qing and Wei, Yu-Quan and Wang, Wei},
title = {EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors},
journal = {Science Advances},
year = {2023},
volume = {9},
number = {48},
doi = {10.1126/sciadv.adg9721}
}
EUVIMED